Evidence map›Paper›PMID 32232681›Full record

ReviewDrug delivery and translational research2020

Implantable anti-angiogenic scaffolds for treatment of neovascular ocular pathologies.

Biplab Sarkar, Zain Siddiqui, Ka Kyung Kim, Peter K Nguyen, Xavier Reyes, Trevor J McGill, Vivek A Kumar

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug delivery and translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Self-assembling Peptide Hydrogels Facilitate Vascularization in Two-Component Scaffolds.Chemical engineering journal (Lausanne, Switzerland : 1996) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Biplab SarkarDepartment of Biomedical Engineering, New Jersey Institute of Technology, 138 Warren St. LSEB 316, Newark, NJ, 07102, USA.ORCID https://orcid.org/0000-0002-9298-2392
Zain SiddiquiDepartment of Biomedical Engineering, New Jersey Institute of Technology, 138 Warren St. LSEB 316, Newark, NJ, 07102, USA.
Ka Kyung KimDepartment of Biomedical Engineering, New Jersey Institute of Technology, 138 Warren St. LSEB 316, Newark, NJ, 07102, USA.
Peter K NguyenDepartment of Biomedical Engineering, New Jersey Institute of Technology, 138 Warren St. LSEB 316, Newark, NJ, 07102, USA.
Xavier ReyesDepartment of Biomedical Engineering, New Jersey Institute of Technology, 138 Warren St. LSEB 316, Newark, NJ, 07102, USA.
Trevor J McGillCasey Eye Institute, Oregon Health & Science University, Portland, OR, 97239, USA.
Vivek A KumarDepartment of Biomedical Engineering, New Jersey Institute of Technology, 138 Warren St. LSEB 316, Newark, NJ, 07102, USA. vak@njit.edu.ORCID https://orcid.org/0000-0001-7536-9281
New Jersey Institute of Technology · USOregon Health & Science University · USRutgers, The State University of New Jersey · US

Funding

Peptide hydrogels for management and treatment of neovascular posterior segment diseasesR15EY029504 · NEI · NEW JERSEY INSTITUTE OF TECHNOLOGY · PI KUMAR, VIVEK · 2019 to 2020
$508k
Directorate for Engineering IIP 1903617NEI NIH HHS R15 EY029504
6 · The paper itself

Abstract

The retinal physiology can accrue oxidative damage and inflammatory insults due to age and metabolic irregularities. Two notable diseases that involve retinal and choroidal neovascularization are proliferative diabetic retinopathy and wet age-related macular degeneration. Currently, these diseases are mainly treated with anti-VEGF drugs (VEGF = vascular endothelial growth factor), generally on a monthly dosage scheme. We discuss recent developments for the treatment of these diseases, including bioactive tissue-engineered materials, which may reduce frequency of dosage and propose a path forward for improving patient outcomes. Graphical abstract Development of materials for long-term intravitreal delivery for management of posterior segment diseases.

Indexed as

Choroidal NeovascularizationDiabetic RetinopathyRetinal NeovascularizationWet Macular DegenerationAngiogenesis InhibitorsHumansVascular Endothelial Growth Factor AAngiogenesis InhibitorsVascular Endothelial Growth Factor AAge-related macular degenerationAnti-angiogenic materialsDiabetic retinopathyHydrogelPathological neovascularizationPeptide nanofibersSelf-assembly

Identifiers

PMID32232681
PMCPMC7483832
OpenAlexW3013314594

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.